Riley Sharon L.

Avg. Two Year Performance

59% Avg. Purchase Return
26% Compound
(58%) Avg. Sale Return
(26%) Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return6%15%32%50%59%
Purchase Success Rate4 of 66 of 65 of 64 of 65 of 6
Average Sale Return(< 1%)(14%)(23%)(61%)(58%)
Sale Success Rate1 of 40 of 41 of 41 of 40 of 4

Heska Corp.

Drugs » Biotechnology

Director:

Holdings: 0 shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--